Platinum-resistant and refractory ovarian cancer: Second-line treatment options

American Journal of Cancer

Volumn 2, Issue 1, 2003, Pages 1-13

  Alvarez, Angeles A ^a   Clarke Pearson, Daniel L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MELPHALAN; NAVELBINE; PACLITAXEL; PLATINUM; TOPOTECAN;

ALOPECIA; ANEMIA; ARTHRALGIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BULLOUS SKIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG COST; DRUG TOLERABILITY; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEALTH CARE COST; HUMAN; HYPERSENSITIVITY; LIVER TOXICITY; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PAIN; PALLIATIVE THERAPY; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; SALVAGE THERAPY; SKIN ABRASION; SKIN MANIFESTATION; SKIN TINGLING; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; VERTIGO; VOMITING;

EID: 0042322495     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200302010-00001     Document Type: Review

References (77)

1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6
2. Blackledge G, Lawton F, Redman C, et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patients treatment and the design of phase II trials. Br J Cancer 1989; 59: 650-3
3. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991; 9: 1801-5
4. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-93
5. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994; 12: 1748-53
6. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000; 5: 26-35
7. Gordon AN, Fleagle JT, Guthric D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-22
8. Rose PG, Fusco N, Fluellen L, et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998; 16: 1494-7
9. Kavanagh JJ, Kudelka AP, de Leon CG, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996; 2: 837-42
10. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9
11. Zanotti KM, Belinson JL, Kennedy AW, et al. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol Oncol 2000; 79: 211-5
12. Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 2002; 20: 2365-9
13. ten Bokkel H, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183-93
14. Bolis G, Parazzini F, Scarfone G, et al. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol Oncol 1998; 72: 60-4
15. Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18: 3093-100
16. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-93
17. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 6: 3345-52
18. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14: 3056-61
19. Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994; 12: 2301-8
20. Piccart MJ, Gore M, ten Bokkel H, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995; 87: 676-81
21. Seymour MT, Mansi JL, Gallagher CJ, et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994; 69: 191-5
22. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994; 12: 60-3
23. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 405-10
24. Lund B, Neijt JP. Gemcitabine in cisplatin-resistant ovarian cancer. Semin Oncol 1996; 23: 72-6
25. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530-3
26. Burger RA, DiSaia PJ, Roberts JA, et al. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 1999; 72: 148-53
27. Sorensen P, Hoyer M, Jakobsen A, et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol 2001; 81: 58-62
28. Bajetta E, Di Leo A, Biganzoli L, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1996; 14: 2546-51
29. Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992; 10: 243-8
30. Sorensen P, Pfeiffer P, Bertelsen K. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. Gynecol Oncol 1994; 56: 75-8
31. Markman M, Kennedy A, Sutton G, et al. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol 1992; 70: 272-4
32. Scarfone G, Villa A, Parazzini F, et al. A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy. Tumori 1999; 85: 217-9
33. Markman M, Blessing JA, Moore D, et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 1997; 69: 226-9
34. Gore ME, Fryatt I, Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36: 207-11
35. Markman M, Kennedy A, Webster K, et al. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. Gynecol Oncol 2002; 65: 434-6
36. Kavanagh J, Tresukosol D, Edwards C, et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995; 13: 1584-8
37. Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 1999; 4: 87-94
38. Lau DH, Xue L, Young LJ, et al. Paclitaxel (taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999; 14: 31-6
39. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2: 1843-9
40. Guchelaar HJ, ten Napel CH, de Vries EG, et al. Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. Clin Oncol 1994; 6: 40-8
41. Tresukosol D, Kudelka AP, Gonzales DL, et al. Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer. Fur J Gynaecol Oncol 1996; 17: 188-91
42. Eisenhauer EA, ten Bokkel H, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-6
43. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15: 187-92
44. Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol 2001; 83: 257-62
45. Markman M, Kennedy A, Webster K, et al. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol Oncol 2000; 79: 116-9
46. Rose PG, Gordon NH, Fusco N, et al. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol Oncol 2000; 78: 228-34
47. Clarke-Pearson DL, Van Le L, Iveson T, et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 2001; 19: 3967-75
48. Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 2002; 38: 57-63
49. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32: 2747-55
50. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 288-91
51. Extra JM, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of Taxotere (RP 50976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993; 53: 1037-42
52. Verschraegen CF, Sittisomwong T, Kudelka AP, et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 2000; 18: 2733-9
53. de Jong RS, Mulder NH, Dijksterhuis D, et al. EG: Review of current clinical experience with prolonged (oral) etoposide in cancer treatment. Anticancer Res 1995; 15: 2319-30
54. Dombernowsky P, Nissen NI, Larsen V. Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4′ -demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors. Cancer Chemother Rep 1972; 56: 71-82
55. Edmonson JH, Decker DG, Malkasian GD, et al. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents. Gynecol Oncol 1978; 6: 7-9
56. Slayton RE, Creasman WT, Petty W, et al. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study. Cancer Treat Rep 1979; 63: 2089-92
57. Maskens AP, Armand JP, Lacave AJ, et al. Phase II clinical trial of VP-16-213 in ovarian cancer. Cancer Treat Rep 1981; 65: 329-30
58. Aguilar PJ, Flores-Picazo Y, Perez-Urizar J, et al. Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmacoeconomic perspectives. Arch Med Res 1999; 30: 212-5
59. Ozols RF. Oral etoposide for the treatment of recurrent ovarian cancer. Drugs 1999; 58 Suppl. 3: 43-9
60. Huang P, Chubb S, Hertel LW, et al. Action of 2′,2′ -difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-7
61. Cortes-Funes H, Martin C, Abratt R, et al. Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer. Anticancer Drugs 1997; 8: 582-7
62. Johnson SA, Harper P, Hortobagyi GN, et al. Vinorelbine: an overview. Cancer Treat Rev 1996; 22: 127-42
63. Besenval M, Delgado M, Demarez JP, et al. Safety and tolerance of navelbine in phase I-II clinical studies. Semin Oncol 1989; 16: 37-40
64. Budman DR. Vinorelbine (navelbine): a third-generation vinca alkaloid. Cancer Invest 1997; 15: 475-90
65. Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 1997; 17: 146S-54S
66. Cohen MH, Creaven PJ, Tejada F, et al. Phase I clinical trial of isophosphamide (NSC-109724). Cancer Chemother Rep 1975; 59: 751-5
67. van der Burg ME, de Wit R, van Putten WL, et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer 2002; 7 (86): 19-25
68. Bolis G, Scarfone G, Giardina G, et al. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer: Associazione per la Ricerca in Ginecologia Oncologia. Gynecol Oncol 2001; 81: 3-9
69. Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 2002; 20: 1161-3
70. Donato ML, Gershenson DM, Wharton JT, et al. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol 2001; 82: 420-6
71. Ozols RF, Gore M, Trope C, et al. Intraperitoneal treatment and dose-intense therapy in ovarian cancer. Ann Oncol 1999; 10 Suppl. 1: 59-64
72. Ozols RF, Thigpen JT, Dauplat J, et al. Advanced ovarian cancer: dose intensity. Ann Oncol 1993; 4 Suppl. 4: 49-56
73. Hatch KD, Beecham JB, Blessing JA, et al. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen: a Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991; 68: 269-71
74. Markman M, Iseminger KA, Hatch KD, et al. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol 1995; 62: 4-6
75. Wilailak S, Linasmita V, Srisupundit S. Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer. Anticancer Drugs 2001; 12: 719-24
76. Wiernik PH, Greenwald ES, Ball H, et al. High-dose megestrol acetate in the treatment of patients with ovarian cancer who have undergone previous treatment: Eastern Cooperative Oncology Group Study PD884. Am J Clin Oncol 1998; 21: 565-7
77. Ahlgren JD, Ellison NM, Gottlieb RJ, et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993; 11: 1957-68